151 related articles for article (PubMed ID: 30568177)
21. PARP Inhibitors for Cancer Therapy.
Lin KY; Kraus WL
Cell; 2017 Apr; 169(2):183. PubMed ID: 28388401
[TBL] [Abstract][Full Text] [Related]
22. Epithelial ovarian cancer.
Lheureux S; Gourley C; Vergote I; Oza AM
Lancet; 2019 Mar; 393(10177):1240-1253. PubMed ID: 30910306
[TBL] [Abstract][Full Text] [Related]
23. SEOM clinical guideline in ovarian cancer (2020).
Redondo A; Guerra E; Manso L; Martin-Lorente C; Martinez-Garcia J; Perez-Fidalgo JA; Varela MQ; Rubio MJ; Barretina-Ginesta MP; Gonzalez-Martin A
Clin Transl Oncol; 2021 May; 23(5):961-968. PubMed ID: 33515422
[TBL] [Abstract][Full Text] [Related]
24. Do increased tumor infiltrating lymphocytes co-existing with Homologous Recombination Deficiency provide clues to enhance immunotherapy of ovarian cancer?
Ledermann JA
Gynecol Oncol; 2019 May; 153(2):213-214. PubMed ID: 31027611
[No Abstract] [Full Text] [Related]
25. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
[TBL] [Abstract][Full Text] [Related]
26. More breast cancer patients could benefit from PARP inhibitors.
Cancer; 2017 Sep; 123(18):3433. PubMed ID: 28880389
[No Abstract] [Full Text] [Related]
27. Rucaparib: a novel PARP inhibitor for
Colombo I; Lheureux S; Oza AM
Drug Des Devel Ther; 2018; 12():605-617. PubMed ID: 29606854
[TBL] [Abstract][Full Text] [Related]
28. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
29. It's About Time!
Tempero M
J Natl Compr Canc Netw; 2020 Feb; 18(2):115. PubMed ID: 32023523
[No Abstract] [Full Text] [Related]
30. Pancreatic cancer: BRCA mutation and personalized treatment.
Luo G; Lu Y; Jin K; Cheng H; Guo M; Liu Z; Long J; Liu C; Ni Q; Yu X
Expert Rev Anticancer Ther; 2015; 15(10):1223-31. PubMed ID: 26402249
[TBL] [Abstract][Full Text] [Related]
31. [BRCA diagnostics of ovarian cancer : Molecular tumor testing since the introduction of PARP inhibitor therapy].
Löser H; Heydt C; Büttner R; Markiefka B
Pathologe; 2017 Mar; 38(2):117-126. PubMed ID: 28258387
[TBL] [Abstract][Full Text] [Related]
32. [BRCA1 and BRCA2 - pathologists starting kit].
Škapa P
Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
[TBL] [Abstract][Full Text] [Related]
33. Rucaparib: First Global Approval.
Syed YY
Drugs; 2017 Apr; 77(5):585-592. PubMed ID: 28247266
[TBL] [Abstract][Full Text] [Related]
34. A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
van der Biessen DAJ; Gietema JA; de Jonge MJA; Desar IME; den Hollander MW; Dudley M; Dunbar M; Hetman R; Serpenti C; Xiong H; Mittapalli RK; Timms KM; Ansell P; Ratajczak CK; Shepherd SP; van Herpen CML
Invest New Drugs; 2018 Oct; 36(5):828-835. PubMed ID: 29313279
[TBL] [Abstract][Full Text] [Related]
35. Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?
Duma N; Gast KC; Choong GM; Leon-Ferre RA; O'Sullivan CC
Curr Oncol Rep; 2018 Jun; 20(8):63. PubMed ID: 29884921
[TBL] [Abstract][Full Text] [Related]
36. Niraparib for the treatment of ovarian cancer.
Kanjanapan Y; Lheureux S; Oza AM
Expert Opin Pharmacother; 2017 Apr; 18(6):631-640. PubMed ID: 28299955
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
Secord AA; Barnett JC; Ledermann JA; Peterson BL; Myers ER; Havrilesky LJ
Int J Gynecol Cancer; 2013 Jun; 23(5):846-52. PubMed ID: 23666017
[TBL] [Abstract][Full Text] [Related]
38. PARP inhibitors: pitfalls and promises.
Infante JR; Burris HA
Lancet Oncol; 2013 Aug; 14(9):798-9. PubMed ID: 23810789
[No Abstract] [Full Text] [Related]
39. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
Liu JF; Matulonis UA
Curr Oncol Rep; 2016 May; 18(5):29. PubMed ID: 26984416
[TBL] [Abstract][Full Text] [Related]
40. Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients.
Capoluongo E; Ellison G; López-Guerrero JA; Penault-Llorca F; Ligtenberg MJL; Banerjee S; Singer C; Friedman E; Markiefka B; Schirmacher P; Büttner R; van Asperen CJ; Ray-Coquard I; Endris V; Kamel-Reid S; Percival N; Bryce J; Röthlisberger B; Soong R; de Castro DG
Semin Oncol; 2017 Jun; 44(3):187-197. PubMed ID: 29248130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
